Clinical Trials Browser

Phase 2 × Has announcements × belzutifan × Clear all

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2024-12-03

MK-6482-004

Phase 2 Active not recruiting

50 enrolled 1 FDA

von Hippel-Lindau Disease